Autologous Bone Marrow Transplantation - Blog Science Connections

Acetaldophosphamide—A New Stable
Aldophosphamide Analogue for
Ex Vivo Chemotherapy
of Leukemia
Miloslav Beran, Yuqiang Wang, and David Farquhar
Latent contamination of remission bone marrow with malignant cells is a
potential hazard when such marrow is used for autologous rescue after highdose
chemotherapy. Although not proved necessary beyond doubt, in vitro
treatment of such marrow is logical. A drug used for such purging should
ideally kill leukemic cells yet spare bone marrow stem cells. Here we report the
in vitro hematopoietic effects of the new stable aldophosphamide analogue,
acetaldophosphamide (A-ALD) and compare its activity with that of 4-
hydroperoxycyclophosphamide (4-HC).
MATERIALS AND METHODS
Drugs
We have synthesized A-ALD at our institution. It has a molecular weight of
379, and when diluted in phosphate-buffered saline (PBS) (pH 7.2), it has a
half-life of 52 hours at 37°C. Before use, it was diluted in PBS and used either
fresh or stored at -20°C and used after thawing. The 4-HC was a gift from
Asta-Werke (Bielefeld, Federal Republic of Germany). It was used immediately
after dilution in PBS.
163